David Grainger
British life-sciences investor and drug developer, venture partner at Medicxi and chief executive of Methuselah Health.
本條目暫未提供此語言版本，現顯示英文原文。
David Grainger (born 12 October 1966) is a British life-sciences investor and drug developer. He is a co-founder and venture partner of Medicxi, a European venture capital firm focused on life sciences, having previously worked in the life-sciences practice of Index Ventures.
He is chief executive of Methuselah Health, a United Kingdom company applying proteomics to the development of treatments for age-related disease, and was formerly Chief Innovation Officer of Centessa Pharmaceuticals.
Grainger has co-founded and chaired several biotechnology companies, among them XO1, later acquired by Janssen Pharmaceuticals, and Morphogen-IX, and led investments including Padlock Therapeutics, acquired by Bristol-Myers Squibb. He has also written on the pharmaceutical industry for Forbes.
教育程度
- University of Cambridge